Cargando…

CCR6(+) Th cell distribution differentiates systemic lupus erythematosus patients based on anti-dsDNA antibody status

BACKGROUND: Systemic lupus erythematosus (SLE) disease has been shown to be associated with the generation of multiple auto-antibodies. Among these, anti-dsDNA antibodies (anti-DNAs) are specific and play a pathogenic role in SLE. Indeed, anti-DNA(+) SLE patients display a worse disease course. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Wei, Jiang, Zhenyu, Wu, Jiang, Jiang, Yanfang, Zhao, Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808313/
https://www.ncbi.nlm.nih.gov/pubmed/29441231
http://dx.doi.org/10.7717/peerj.4294
Descripción
Sumario:BACKGROUND: Systemic lupus erythematosus (SLE) disease has been shown to be associated with the generation of multiple auto-antibodies. Among these, anti-dsDNA antibodies (anti-DNAs) are specific and play a pathogenic role in SLE. Indeed, anti-DNA(+) SLE patients display a worse disease course. The generation of these pathogenic anti-DNAs has been attributed to the interaction between aberrant T helper (Th) cells and autoimmune B cells. Thus, in this study we have investigated whether CCR6(+)Th cells have the ability to differentiate SLE patients based on anti-DNA status, and if their distribution has any correlation with disease activity. METHODS: We recruited 25 anti-DNA(+) and 25 anti-DNA(−) treatment-naive onset SLE patients, matched for various clinical characteristics in our nested matched case-control study. CCR6(+) Th cells and their additional subsets were analyzed in each patient by flow cytometry. RESULTS: Anti-DNA(+) SLE patients specifically had a higher percentage of Th cells expressing CCR6 and CXCR3. Further analysis of CCR6(+) Th cell subsets showed that anti-DNA(+) SLE patients had elevated proportions of Th9, Th17, Th17.1 and CCR4/CXCR3 double-negative (DN) cells. However, the proportions of CCR6(−) Th subsets, including Th1 and Th2 cells, did not show any association with anti-DNA status. Finally, we identified a correlation between CCR6(+) Th subsets and clinical indicators, specifically in anti-DNA(+) SLE patients. CONCLUSIONS: Our data indicated that CCR6(+) Th cells and their subsets were elevated and correlated with disease activity in anti-DNA(+) SLE patients. We speculated that CCR6(+) Th cells may contribute to distinct disease severity in anti-DNA(+) SLE patients.